Collaboration across industry is core to our business model. We are committed to partnering with R&D based global pharma and biotech companies to bring innovative medicines to patients. With our highly recognized and comprehensive in-house resources and competency from early stage discovery to clinical development and operation as well as strong track record of successful new drug filings in China and other countries, we are uniquely positioned as a clinical development partner in China for global drug approval. We have successfully licensed the global rights of several assets from Jiangsu Hengrui Medicine, a top Chinese pharmaceutical company, and quickly developed them into 7 phase 2 and 1 phase 1 studies globally.

We continue to actively seek new in-licensing and co-development opportunities. At present, the company focuses on the global and/or greater China rights of drugs for immuno-inflammatory diseases and other unmet medical need areas. We welcome opportunities for partnership around the globe. Please contact us at: BD@reistonebio.com.